Poly [ADP-ribose] polymerase 2 mRNA (PARP2 mRNA)

Poly [ADP-ribose] polymerase 2 (PARP2) mRNA is the transcript encoding the PARP2 enzyme, which plays a critical role in the cellular response to DNA damage, specifically in the base excision repair (BER) pathway (NCBI Gene ID: 10038). The PARP2 protein product works alongside PARP1 to detect DNA strand breaks and catalyze the synthesis of poly(ADP-ribose) chains, which recruit repair factors to the site of damage (UniProt P51722). While most clinical focus has been on small molecule inhibitors that target the PARP2 protein (e.g., Olaparib, Niraparib), the mRNA itself is a target for gene-silencing technologies like small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) (PubMed: 21552404). By reducing PARP2 mRNA levels, these therapies aim to deplete the cellular pool of PARP2 protein, thereby sensitizing cancer cells to DNA-damaging agents or inducing synthetic lethality in cells with homologous recombination deficiencies, such as BRCA1/2 mutations (PubMed: 15155835). PARP2 also plays distinct roles in erythropoiesis and T-cell development, making its specific regulation via mRNA targeting a subject of interest for minimizing the broad toxicities sometimes seen with pan-PARP inhibitors. Research suggests that PARP2 mRNA expression levels may serve as a predictive biomarker for therapeutic response in various malignancies, including breast and ovarian cancers (PubMed: 23239740). However, therapeutic challenges include the efficient delivery of RNA-based drugs to tumor sites and potential off-target effects associated with nucleic acid therapies.

Other names

PARP-2 mRNApADPRT-2 mRNAPoly[ADP-ribose] synthase 2 mRNAARTD2 mRNAhPARP-2 mRNAADPRT2 mRNAADPRTL2 mRNA

RNA interference (RNAi) or antisense-mediated degradation of the transcript, leading to the inhibition of PARP2 protein synthesis and subsequent impairment of DNA repair mechanisms (PubMed: 21552404).